Department of Clinical Microbiology, Saskatoon and District Health and St Paul's Hospital, Saskatoon, Saskatchewan, Canada
Sir,
Recently Legg & Bint1 asked, "Whether the quinolones would be put in their place by the pneumococcus?" Since this article, two new fluoroquinolones have been released in the USA, with another under review. We examined >1000 recent clinical isolates of Streptococcus pneumoniae for their susceptibility to two of these fluoroquinolones, moxifloxacin and gatifloxacin.
Using the microbroth dilution method,2 we tested 1037 strains isolated from sputum, CSF and blood. The Table shows the MIC90s of the two drugs: gatifloxacin 0.5 mg/L and moxifloxacin 0.25 mg/L. These data corroborate those of studies in which the agents were tested separately against S. pneumoniae.
|
Clearly, MICs tell us only so much; future fluoroquinolones may be more active in the test tube but their tissue/serum levels may not permit adequate therapeutic indices over the entire dosing period in order to minimize the selection of resistance.
Legg & Bint were right to ask the question, but the answer as always is it depends.
Notes
J Antimicrob Chemother 2000; 46: 323
* Correspondence address. Royal University Hospital, 103 Hospital Drive, Saskatoon, SK, Canada SN7 4PI. Tel: +1-306-655-6943; Fax: +1-306-655-6947; E-mail: blondeauj{at}sdh.sk.ca
References
1
.
Legg, J. M. & Bint, A. J. (1999). Will pneumococci put quinolones in their place? Journal of Antimicrobial Chemotherapy 44, 4257.
2 . National Committee for Clinical Laboratory Standards. (1999). Performance Standards for Antimicrobial Susceptibility Testing: M7-S9. NCCLS, Vilanova, PA.
3 . Blondeau, J. M., Borsos, S. & Drlica, K. (1999). Mutation prevention concentration of moxifloxacin and levofloxacin against clinical isolates of S. pneumoniae and S. aureus. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 2629, 1999. Abstract 032.E. American Society for Microbiology, Washington, DC.